Polio: Is it Really Gone?

Philip Dawe, BEng, MD; and John M. Embil, MD, FRCPC

Until the development of widespread immunization programs, poliomyelitis was a disease that struck fear and caused devastation throughout the world with its disabling effects. Since the advent of the two immunizations against the poliovirus in the 1950s and 1960s, there has been a dramatic decline in the incidence of poliomyelitis in Canada and the remainder of the Western Hemisphere.

Despite successes in our country, global organizations continue to be frustrated in their pursuit of worldwide eradication of the virus.

Despite successes in our country, global organizations, such as the World Health Organization, continue to be frustrated in their pursuit of worldwide eradication of the virus. Polio has made recent headlines, such as the case in Minnesota when a religious sect opposed to vaccinations suffered an outbreak of infection caused by the poliovirus, reminding us that the threat is not gone.

What is poliovirus?

Poliovirus is an RNA nonenveloped enterovirus. There are three serologic types based on different antigenic determinants on the outer capsid proteins. Since there is little cross-reactivity between serotypes, protection from the disease requires antibodies against each of the three types.

How is poliovirus transmitted?

Poliovirus is traditionally transmitted via the fecal-oral route. As a result, poor sanitation in underdeveloped areas of the world plays a very important role in maintaining the momentum of epidemics. Its prevalence in underdeveloped countries also puts travellers to those areas at risk of infection.

Most cases in North America are the result of infection from the live attenuated vaccine or oral polio vaccine (OPV). This can happen as a result of the attenuated virus reverting to a more virulent strain, but occurs more commonly in immunocompromised patients receiving the live vaccine. There have been 11 reported cases of vaccine-associated paralytic polio (VAPP) in Canada since 1980. The risk of developing VAPP is about one per 2.5 million doses administered, but is 2,000 times higher among immunodeficient patients.

The result of widespread vaccination has been eradication of indigenous wildtype disease. The last outbreak of polio in Canada was in 1959 and resulted in 1,887 paralytic cases. Since that time there have been only isolated infections. Between 1978 and 1989, there were 11 paralytic cases in unimmunized contacts of

imported cases within a religious group. In 1993, 22 asymptomatic cases of imported wild polio were reported within the same religious group. In none of these cases was the spread of the virus seen outside the unimmunized community, presumably due to herd immunity.

Poor sanitation in underdeveloped areas of the world plays a very important role in maintaining the momentum of epidemics.

What are the manifestations of polio?

Although poliomyelitis is the most publicized and most feared outcome of poliovirus infection, asymptomatic infection is the most common course (80% to 90%). In 1% to 5% of cases, patients will develop nonparalytic polio (or abortive poliomyelitis). Following a three- to six-day incubation period, these patients will present with flu-like symptoms of:

- fever,
- malaise,
- sore throat,
- anorexia,
- myalgias and
- headache.

This condition will typically resolve within three days.

Another 1% to 10% will develop nonparalytic aseptic meningitis. These patients will experience similar symptoms and exhibit similar signs to those with nonparalytic polio, but will also experience signs and symptoms of meningeal inflammation, such as neck and back stiffness and can also experience muscle spasms. Examination of the cerebrospinal fluid (CSF) reveals lymphocytic pleocytosis, normal glucose level, normal or slightly elevated protein levels.

The least common presentation is that of paralytic poliomyelitis. After replication in the oropharynx and intestinal tract, the virus spreads hematogenously to the central nervous system (CNS). In the CNS, poliovirus preferentially replicates in the motor neuron cell bodies. Infection of these cells causes paralysis. After one to several days, signs of aseptic meningitis are followed by severe back, neck and muscle pain and by development of muscle weakness. In some cases, the disease appears to be biphasic, with aseptic meningitis followed first by apparent recovery but then (one or two days later) by the return of fever and the development of paralysis. Since the motor nerve cell bodies are affected, sensation remains normal, although patients may describe sensory symptoms. Paralytic polio has traditionally been classified into three categories:

1. Spinal polio: This category involves infection of the motor neuron cell bodies in the spinal cord found in the anterior horn that control primarily skeletal and respiratory muscles. Resultant weakness is typically asymmetric and more proximal than distal and the legs are the most commonly involved limbs. Although any patient can present with any degree of disability, infected children tend to have more isolated paralysis (*e.g.*, of only one limb), while adults tend to have more generalized manifestations. Examination reveals typical lower motor neuron signs, such as weakness, decreased or absent reflexes, fasciculations and decreased muscle tone

2. Bulbar polio: Infection of the cranial nerve cell bodies can lead to dysphagia, difficulty in handling secretions, dysphonia or respiratory insufficiency (due to aspiration, involvement of the respiratory centre in the medulla or paralysis of the phrenic nerve). Severe medullary involvement may even lead to circulatory collapse. This can clearly be a life-threatening condition that may require indefinite respiratory support
3. Bulbospinal polio: This is simply a combination of spinal and bulbar polio

Most patients will recover some function within weeks to months of initial infection, but unfortunately approximately two-thirds of patients will have permanent neurologic sequelae.

What is post-polio syndrome?

Post-polio syndrome presents as a new, but insidious onset of symptoms 10 to 40 years after initial infection. Symptoms include:

- weakness in either previously affected limbs or in limbs not thought to have been involved originally,
- general fatigue or exhaustion with minimal activity,
- myalgias,
- arthralgias,
- dysphagia,
- respiratory problems,
- sleep-related problems, such as sleep apnea and
- intolerance to cold.

Risk factors include the female gender and increasing time from acute infection. Although the pathophysiology is unclear, post-polio syndrome is thought to be due to progressive dysfunction and loss of motor neurons that compensated for the neurons lost during the original infection rather than persistent or reactivated poliovirus infection.

How is polio diagnosed?

In addition to the clinical findings described above, the physician can seek to isolate the virus in a suspected case. Throat, stool, serum and CSF cultures should be sent for poliovirus. Where available, polymerase chain reaction (PCR) analysis of these samples can be used to identify the virus, as it is highly sensitive (95%) and specific (80%) and is generally quicker than culture. In addition to confirming the diagnosis, these results can help to identify the source of the infection as either from a live OPV or from a "wildtype" virus. Polio is a reportable disease and any positive test results should be forwarded to the physician's provincial Ministry of Health.

How is polio treated?

There is no cure for polio and as a result, supportive therapy is the only available option. The patient's requirements will dictate the therapy required, which can range from physiotherapy, special braces and slings for affected limbs to ventilatory support for respiratory weakness. The latter requirement spawned the now-infamous iron lung—weighing as much as a small car, the iron lung was effective at providing respiratory support, but was clearly very restrictive.

Dr. Dawe is a Resident in Family Medicine, University of Manitoba, Winnipeg, Manitoba.

Dr. Embil is a Consultant, Infectious Diseases and Associate Professor, University of Manitoba. He is also the Medical Director, Infection Prevention and Control Program, Health Science Centre and Winnipeg Regional Health Authority, Winnipeg, Manitoba.

Table 1

Current Health Canada immunization guidelines against poliovirus

Age group	Immunization schedule	Comments
Children	• 2 months • 4 months • 6 months • 18 months • 4-6 years	• The 6 months immunization is not required but can be given for convenience
Unimmunized adults	• Two doses given at 4 to 8 week intervals • Third dose given 6 to 12 months later	• Routine immunization of unimmunized adults is not considered necessary due to negligible risk of exposure to wild virus • Immunization of adults is only recommended in adults who are unimmunized and at increased risk of exposure to poliovirus (*i.e.*, travellers to endemic areas, laboratory or healthcare workers)

How is polio prevented?

There are two polio vaccines available:

- the live-attenuated vaccine given orally (Sabin vaccine, OPV) and
- the inactivated polio vaccine (IPV) (Salk vaccine) given intramuscularly (IM).

Both vaccines confer protection against all three serotypes of the poliovirus. The development of the two vaccines was the result of a heated rivalry between two researchers, Jonas Salk and Albert Sabin. Salk developed the IPV and was first to mass-produce his product which was field-tested in 1954. Sabin developed the OPV, which became available in 1962.

Each vaccine has its advantages and disadvantages. IPV is considered to be safer to the recipient due to its inactivated form. However, it is somewhat less effective (90% after two initial doses given at least six weeks apart, but up to 100% with a booster six to 12 months later). It also provides IgG humoral immunity, but very little to no IgA mucosal (or intestinal) immunity. As a result, it cannot prevent transmission. Although neither proven effective nor recommended by Health Canada, booster IPV shots are frequently given to immunized patients who will be travelling to endemic areas.

Polio remains a very disabling and potentially life-threatening disease that, with continued effort, could be completely eradicated.

OPV has the benefit of interrupting the spread to others by conferring intestinal (IgA, mucosal) immunity to the recipient. It provides lifelong immunity and can be given very easily since it is a single dose by mouth. The main

disadvantage lies in the fact that it is a live-attenuated virus that can, in some cases, infect the recipient or the recipient's contacts. Another disadvantage when considering immunization in the developing world is the need for the vaccine to be refrigerated.

What are the current polio immunization guidelines in Canada?

Because of virtual eradication of the polio in North America and the persistent risk of VAPP, OPV is no longer used in either Canada or the US. IPV is the vaccine of choice and current Canadian polio immunization guidelines are found in Table 1. For the official recommendations, including more detailed information regarding specific cases, visit the Health Canada website: http://www.phac-aspc.gc.ca/publicat/cig-gci/pdf/cig-gci-2006_e.pdf.

Through widespread vaccination, the general population may have forgotten its terrifying renown, but polio remains a very disabling and potentially life-threatening disease that, with continued effort, could be completely eradicated. Physicians need to ensure vaccination of their patients and remember that the disease continues to exist. Continued preventative measures can help prevent North American outbreaks seen as recently as October 2005 in Minnesota.

cme

Additional Reading
1. Kidd D, Williams AJ, Howard RS: Poliomyelitis. Postgrad Med J 1996: 72(853);641-7.
2. Howard RS: Poliomyelitis and the Postpolio Syndrome. BMJ. 2005; 330(7503):1314-8.